Landos Biopharma is a clinical-stage biopharmaceutical company focused on the development of oral therapeutics for patients with certain immunology diseases. Co.'s main candidate is NX-13, an oral, gut-selective NLRX1 agonist. In addition to NX-13, Co. has several preclinical product candidates: LABP-73, an oral, small molecule NLRX1 pathway agonist for the treatment of asthma and Chronic Obstructive Pulmonary Disease; LABP-66, an oral, small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis, and Alzheimer's disease; and LABP-69, an oral, small molecule PLXDC2 pathway agonist in development for the treatment of diabetic nephropathy and rheumatoid arthritis. We show 14 historical shares outstanding datapoints in our LABP shares outstanding history coverage, used to compute LABP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LABP market cap history over the course of time is important for investors
interested in comparing LABP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LABP versus a peer is one thing; comparing
LABP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LABP can fluctuate over the course of history.
With this page we aim to empower investors researching LABP by allowing them to research the LABP market cap history. |
Free LABP Email Alerts:
Video: The Importance of Market Cap
